Imaging to guide treatment for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at whether detailed scans taken before treatment can predict how well chemo and immunotherapy will work for advanced esophageal cancer. The goal is to improve treatment planning and potentially reduce side effects by personalizing care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have squamous cell esophageal cancer.
- Your cancer is stage II to IVA and can be surgically removed.
- You have not had any prior cancer treatment, like chemotherapy or radiation.
- Your doctor thinks you are strong enough for surgery.
- You are between 18 and 75 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two treatment sequences for people with locally advanced esophageal cancer that cannot be removed with surgery. One group gets immunotherapy first, then chemoradiation; the other gets chemoradiation first, then immunotherapy. The goal is to find which order works better.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
This trial tests giving chemotherapy plus immunotherapy first, followed by standard chemoradiation, for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this approach improves outcomes.
This trial compares two approaches for people with esophageal cancer that has shrunk or disappeared after initial chemotherapy combined with immunotherapy. It looks at whether adding targeted radiation (DCRT) or surgery is better. The goal is to find the most effective next step for eligible patients.
This trial tests a new drug called retlirafusp alfa combined with standard chemoradiotherapy for people with esophageal cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
This trial tests a treatment plan that combines immunotherapy with chemotherapy before possible endoscopic surgery. It is for people with a specific type of esophageal cancer that has not been treated before and is either potentially removable or not suitable for standard surgery.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.